Australia markets closed

Genetron Holdings Limited (GTH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.6800+0.0100 (+0.27%)
At close: 03:50PM EST
Full screen
Trade prices are not sourced from all markets
Previous close3.6700
Open3.6700
Bid3.6700 x 800
Ask3.6800 x 1800
Day's range3.6700 - 3.6800
52-week range2.0790 - 3.8100
Volume3,913
Avg. volume44,622
Market cap116.378M
Beta (5Y monthly)0.47
PE ratio (TTM)N/A
EPS (TTM)-3.6600
Earnings date11 Dec 2023 - 12 Dec 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.34
  • GlobeNewswire

    Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction

    BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a

  • GlobeNewswire

    Genetron Health Announces Receipt of Notification from Nasdaq

    BEIJING, May 23, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated May 17, 2023, indicating that for the

  • GlobeNewswire

    Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement

    BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated Jan